Table 1 Comparison of the advantages and disadvantages of CAR-T therapy and CAR-NK therapy
CAR-T therapy | CAR-NK therapy | |
|---|---|---|
Advantage | Better expansion and persistence Easier transduction and modification Proven prospects for clinical use (many positive clinical results have been reported; CAR-T clinical products approved by FDA) | Various allogeneic sources (PB, UCB, NK cell lines, iPSC) Good safety, no GVHD, CRS and ICANS CAR-dependent killing mechanism and innate cytotoxicity (including ADCC) “Off-the-shelf” products availability and lower cost |
Disadvantage | Single source (patient's autologous T cells) Risk of GVHDs and side effects (CRS, ICANS) Only CAR-dependent killing mechanism Higher cost and low production efficiency (needs to be prepared individually for each patient) Low potential of “off-the-shelf” products | Difficulty in large-scale expansion and short lifespan More difficult to transduce and modify More encouraging clinical results are still needed to prove its application prospects |